A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models

Shiu Wen Huang, Heng Lan Kuo, Ming Tsung Hsu, Yufeng Jane Tseng, Shu Wha Lin, Sheng Chu Kuo, Hui Chin Peng, Jin Cherng Lien, Tur Fu Huang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

A novel benzimidazole derivative, nstpbp5185, was discovered through in vitro and in vivo evaluations for antiplatelet activity. Thro-maboxane receptor (TP) is important in vascular physiology, haemostasis and pathophysiological thrombosis. Nstpbp5185 concentration-dependently inhibited human platelet aggregation caused by collagen, arachidonic acid and U46619. Nstpbp5185 caused a right-shift of the concentration-response curve of U46619 and competitively inhibited the binding of3H-SQ-29548 to TP receptor expressed on HEK-293 cells, with an IC50 of 0.1 uM, indicating that nstpbp5185 is a TP antagonist. In murine thrombosis models, nstpbp5185 significantly prolonged the latent period in triggering platelet plug formation in mesenteric and FeCl3-induced thrombi formation, and increased the survival rate in pulmonary embolism model with less bleeding than aspirin. This study suggests nstpbp5185, an orally selective antithrombotic agent, acting through blockade of TXA2 receptor, may be efficacious for prevention or treatment of pathologic thrombosis.

Original languageEnglish
Pages (from-to)285-299
Number of pages15
JournalThrombosis and Haemostasis
Volume116
Issue number2
DOIs
Publication statusPublished - Aug 1 2016
Externally publishedYes

Fingerprint

Thromboxane Receptors
Platelet Aggregation
Thrombosis
Animal Models
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Fibrinolytic Agents
HEK293 Cells
Hemostasis
Pulmonary Embolism
Arachidonic Acid
Aspirin
Inhibitory Concentration 50
Blood Vessels
Collagen
Blood Platelets
Hemorrhage

Keywords

  • Benzimidazole
  • Mouse thrombotic model
  • Thromboxane receptor antagonist

ASJC Scopus subject areas

  • Hematology

Cite this

A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models. / Huang, Shiu Wen; Kuo, Heng Lan; Hsu, Ming Tsung; Tseng, Yufeng Jane; Lin, Shu Wha; Kuo, Sheng Chu; Peng, Hui Chin; Lien, Jin Cherng; Huang, Tur Fu.

In: Thrombosis and Haemostasis, Vol. 116, No. 2, 01.08.2016, p. 285-299.

Research output: Contribution to journalArticle

Huang, Shiu Wen ; Kuo, Heng Lan ; Hsu, Ming Tsung ; Tseng, Yufeng Jane ; Lin, Shu Wha ; Kuo, Sheng Chu ; Peng, Hui Chin ; Lien, Jin Cherng ; Huang, Tur Fu. / A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models. In: Thrombosis and Haemostasis. 2016 ; Vol. 116, No. 2. pp. 285-299.
@article{903a689d574f4c31a728018694b799f2,
title = "A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models",
abstract = "A novel benzimidazole derivative, nstpbp5185, was discovered through in vitro and in vivo evaluations for antiplatelet activity. Thro-maboxane receptor (TP) is important in vascular physiology, haemostasis and pathophysiological thrombosis. Nstpbp5185 concentration-dependently inhibited human platelet aggregation caused by collagen, arachidonic acid and U46619. Nstpbp5185 caused a right-shift of the concentration-response curve of U46619 and competitively inhibited the binding of3H-SQ-29548 to TP receptor expressed on HEK-293 cells, with an IC50 of 0.1 uM, indicating that nstpbp5185 is a TP antagonist. In murine thrombosis models, nstpbp5185 significantly prolonged the latent period in triggering platelet plug formation in mesenteric and FeCl3-induced thrombi formation, and increased the survival rate in pulmonary embolism model with less bleeding than aspirin. This study suggests nstpbp5185, an orally selective antithrombotic agent, acting through blockade of TXA2 receptor, may be efficacious for prevention or treatment of pathologic thrombosis.",
keywords = "Benzimidazole, Mouse thrombotic model, Thromboxane receptor antagonist",
author = "Huang, {Shiu Wen} and Kuo, {Heng Lan} and Hsu, {Ming Tsung} and Tseng, {Yufeng Jane} and Lin, {Shu Wha} and Kuo, {Sheng Chu} and Peng, {Hui Chin} and Lien, {Jin Cherng} and Huang, {Tur Fu}",
year = "2016",
month = "8",
day = "1",
doi = "10.1160/TH15-12-0993",
language = "English",
volume = "116",
pages = "285--299",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "2",

}

TY - JOUR

T1 - A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models

AU - Huang, Shiu Wen

AU - Kuo, Heng Lan

AU - Hsu, Ming Tsung

AU - Tseng, Yufeng Jane

AU - Lin, Shu Wha

AU - Kuo, Sheng Chu

AU - Peng, Hui Chin

AU - Lien, Jin Cherng

AU - Huang, Tur Fu

PY - 2016/8/1

Y1 - 2016/8/1

N2 - A novel benzimidazole derivative, nstpbp5185, was discovered through in vitro and in vivo evaluations for antiplatelet activity. Thro-maboxane receptor (TP) is important in vascular physiology, haemostasis and pathophysiological thrombosis. Nstpbp5185 concentration-dependently inhibited human platelet aggregation caused by collagen, arachidonic acid and U46619. Nstpbp5185 caused a right-shift of the concentration-response curve of U46619 and competitively inhibited the binding of3H-SQ-29548 to TP receptor expressed on HEK-293 cells, with an IC50 of 0.1 uM, indicating that nstpbp5185 is a TP antagonist. In murine thrombosis models, nstpbp5185 significantly prolonged the latent period in triggering platelet plug formation in mesenteric and FeCl3-induced thrombi formation, and increased the survival rate in pulmonary embolism model with less bleeding than aspirin. This study suggests nstpbp5185, an orally selective antithrombotic agent, acting through blockade of TXA2 receptor, may be efficacious for prevention or treatment of pathologic thrombosis.

AB - A novel benzimidazole derivative, nstpbp5185, was discovered through in vitro and in vivo evaluations for antiplatelet activity. Thro-maboxane receptor (TP) is important in vascular physiology, haemostasis and pathophysiological thrombosis. Nstpbp5185 concentration-dependently inhibited human platelet aggregation caused by collagen, arachidonic acid and U46619. Nstpbp5185 caused a right-shift of the concentration-response curve of U46619 and competitively inhibited the binding of3H-SQ-29548 to TP receptor expressed on HEK-293 cells, with an IC50 of 0.1 uM, indicating that nstpbp5185 is a TP antagonist. In murine thrombosis models, nstpbp5185 significantly prolonged the latent period in triggering platelet plug formation in mesenteric and FeCl3-induced thrombi formation, and increased the survival rate in pulmonary embolism model with less bleeding than aspirin. This study suggests nstpbp5185, an orally selective antithrombotic agent, acting through blockade of TXA2 receptor, may be efficacious for prevention or treatment of pathologic thrombosis.

KW - Benzimidazole

KW - Mouse thrombotic model

KW - Thromboxane receptor antagonist

UR - http://www.scopus.com/inward/record.url?scp=84980348304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980348304&partnerID=8YFLogxK

U2 - 10.1160/TH15-12-0993

DO - 10.1160/TH15-12-0993

M3 - Article

VL - 116

SP - 285

EP - 299

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -